Junxia Li

Geneis is a leading Chinese biotechnology company specializing in precision oncology and high-throughput sequencing. Founded by Dr. Junxia Li, a former executive at BGI, the company focuses on developing liquid biopsy and next-generation sequencing (NGS) solutions for cancer screening, treatment selection, and minimal residual disease (MRD) monitoring. Geneis provides a comprehensive platform for clinical diagnostics, pharmaceutical R&D support, and health management. Their products include the proprietary Geneis Seq series of sequencers and various diagnostic kits for solid tumors, aiming to integrate genomic data into routine clinical practice. The company maintains significant partnerships with pharmaceutical firms to develop companion diagnostics and support clinical trials.